|
|
#1
05-18-2016, 11:34 AM
|
|||
|
|||
AstraZeneca's Lynparza fails in gastric cancer combination test
AstraZeneca's recently approved ovarian cancer drug Lynparza failed to increase overall survival significantly when given with chemotherapy to patients with gastric cancer in a late-stage trial, the drugmaker said on Wednesday.
The news is a setback for the British drugmaker, which reported positive results with an experimental acute asthma drug on Tuesday, although the result may have limited read-across for Lynparza in other cancer settings. AstraZeneca said it was disappointed, but **ted this particular trial was unusual in using a low dose and combining Lynparza with a standard chemotherapy. The company has high hopes for Lynparza, which is central to its goal of building a portfolio of compounds targeting DNA damage response (DDR) mechanisms in cancer cells. أكثر... ??????? ??????: AstraZeneca's Lynparza fails in gastric cancer combination test || ??????: ahlam1399 || ??????: اسم منتداك
|
|
|
العرض الشجري